A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE
Clinical trial NCT04258683 · WITHDRAWN
Trial details
- NCT number
- NCT04258683
- Sponsor
- Canadian Myeloma Research Group
- Status
- WITHDRAWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-02-17
- Primary completion
- 2022-10-31
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.